Section 19B: Opioid antagonist
Section 19B. (a) As used in this section and unless the context clearly requires otherwise, ''opioid antagonist'' shall mean naloxone or any other drug approved by the United States Food and Drug Administration as a competitive narcotic antagonist used in the reversal of overdoses caused by opioids.
(b) Notwithstanding any general or special law to the contrary, a licensed pharmacist may dispense an opioid antagonist in accordance with written, standardized procedures or protocols developed by an actively practicing physician registered with the commissioner to distribute or dispense a controlled substance in the course of professional practice pursuant to section 7, if such procedures or protocols are filed at the pharmacist's place of practice and with the board of registration in pharmacy before implementation.
(c) Before dispensing an opioid antagonist pursuant to this section, a pharmacist shall complete a training program approved by the commissioner on opioid antagonists. The training program shall include, but not be limited to, proper documentation and quality assurance.
(d) A pharmacist dispensing an opioid antagonist under this section shall annually provide to the department the number of times an opioid antagonist is dispensed. Reports made pursuant to this section shall not identify an individual patient, shall be confidential and shall not be public records as defined in clause Twenty-sixth of section 7 of chapter 4.
(e) The department, the board of registration in medicine and the board of registration in pharmacy shall adopt regulations to implement this section.